A prospective randomized controlled trial comparing conventional western medical therapy alone versus conventional western medical therapy combined with kidney-tonifying turbidity-reducing herbal therapy for improving anemia status, iron metabolism, renal function and inflammatory levels, reducing weekly erythropoietin dosage and evaluating safety among non-dialysis adults with stage three to four chronic kidney disease and renal anemia

Hebei Provincial Administration of Traditional Chinese Medicine0 个研究点目标入组 100 人开始时间: 2022年1月1日最近更新: 2026年8月3日

适应症

试验速览

暂无简介。

•Aged 21 to 69 years old, no gender limitation
•Diagnosed with stage 3–4 chronic kidney disease with estimated glomerular filtration rate of 15–59 mL/min/1.73 m² and not receiving dialysis
•Meet the diagnostic criteria for renal anemia: hemoglobin level less than 120 g/L for males and less than 110 g/L for females
•No recombinant human erythropoietin or intravenous iron agents administered within four weeks before enrollment
•Serum ferritin higher than 100 ng/mL and transferrin saturation above 20% to rule out absolute iron deficiency
•Voluntarily participate and sign written informed consent

•Anemia caused by gastrointestinal hemorrhage, hemolysis and hematological diseases including aplastic anemia, myelodysplastic syndrome and thalassemia
•Patients complicated with severe infection, hepatic insufficiency with alanine transaminase/aspartate transaminase levels exceeding three times the upper limit of normal values, malignant tumors or active autoimmune diseases
•Individuals with allergies to ingredients of investigational drugs such as ferrous succinate, erythropoietin and components of traditional Chinese herbal prescriptions
•Pregnant or lactating women
•Participants enrolled in other ongoing clinical trials
•Subjects with poor treatment compliance or those deemed ineligible for enrolment by researchers for other reasons

发起方

Hebei Provincial Administration of Traditional Chinese Medicine